Tania N Petruzziello-Pellegrini1, Philip A Marsden. 1. Department of Laboratory Medicine and Pathobiology, University of Toronto, and Keenan Research Centre, Li KaShing Knowledge Institute, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: Diarrhea-associated hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) continues to be an important public health threat worldwide. Specific therapies are lacking and patient care remains largely supportive. This review discusses the lessons learned from recent events and summarizes key advances made toward understanding the basic mechanisms involved in the pathogenesis of typical HUS. RECENT FINDINGS: The recent German outbreak of a hybrid organism resulted in an unprecedented number of HUS cases and drastically changed the face of typical (diarrhea-associated) HUS. New findings on the roles of complement and the CXCR4/SDF-1 pathway in HUS pathogenesis are summarized and novel therapeutic strategies are highlighted. SUMMARY: A better understanding of STEC-mediated HUS underlies improved therapeutic approaches. New studies of the mechanistic basis of the disease, together with patient-based studies, have led to key findings with important clinical implications.
PURPOSE OF REVIEW: Diarrhea-associated hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) continues to be an important public health threat worldwide. Specific therapies are lacking and patient care remains largely supportive. This review discusses the lessons learned from recent events and summarizes key advances made toward understanding the basic mechanisms involved in the pathogenesis of typical HUS. RECENT FINDINGS: The recent German outbreak of a hybrid organism resulted in an unprecedented number of HUS cases and drastically changed the face of typical (diarrhea-associated) HUS. New findings on the roles of complement and the CXCR4/SDF-1 pathway in HUS pathogenesis are summarized and novel therapeutic strategies are highlighted. SUMMARY: A better understanding of STEC-mediatedHUS underlies improved therapeutic approaches. New studies of the mechanistic basis of the disease, together with patient-based studies, have led to key findings with important clinical implications.
Authors: Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer Journal: N Engl J Med Date: 2011-05-25 Impact factor: 91.245
Authors: Mei Ding; Shiying Cui; Chengjin Li; Serge Jothy; Volker Haase; Brent M Steer; Philip A Marsden; Jeffrey Pippin; Stuart Shankland; Maria Pia Rastaldi; Clemens D Cohen; Matthias Kretzler; Susan E Quaggin Journal: Nat Med Date: 2006-08-13 Impact factor: 53.440
Authors: Udo Buchholz; Helen Bernard; Dirk Werber; Merle M Böhmer; Cornelius Remschmidt; Hendrik Wilking; Yvonne Deleré; Matthias an der Heiden; Cornelia Adlhoch; Johannes Dreesman; Joachim Ehlers; Steen Ethelberg; Mirko Faber; Christina Frank; Gerd Fricke; Matthias Greiner; Michael Höhle; Sofie Ivarsson; Uwe Jark; Markus Kirchner; Judith Koch; Gérard Krause; Petra Luber; Bettina Rosner; Klaus Stark; Michael Kühne Journal: N Engl J Med Date: 2011-10-26 Impact factor: 91.245
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Ansgar Reising; Carsten Hafer; Marcus Hiss; Jan T Kielstein; Jan Menne; Faikah Gueler; Jan Beneke; Silvia Linnenweber-Held; Hermann Haller; Gunilla Einecke Journal: Int Urol Nephrol Date: 2016-01-12 Impact factor: 2.370
Authors: Leticia V Bentancor; Maria P Mejías; Alípio Pinto; Marcos F Bilen; Roberto Meiss; Maria C Rodriguez-Galán; Natalia Baez; Luciano P Pedrotti; Jorge Goldstein; Pablo D Ghiringhelli; Marina S Palermo Journal: MBio Date: 2013-10-01 Impact factor: 7.867